NEW YORK (GenomeWeb) – Gurgaon, India-based Core Diagnostics said today that it has reached an agreement with Guardant Health AMEA under which it will market Guardant's comprehensive liquid biopsy test, Guardant360, in India.
Guardant360 detects cell-free circulating tumor DNA from 73 genes in blood samples from advanced solid-tumor cancer patients, detecting the four major classes of alterations relevant for treatment selection: point mutations, indels, copy number alteration, and fusions/rearrangements.
The assay, run in Guardant's lab, uses a proprietary Digital Sequencing method that incorporates high-efficiency capture, barcoding, and bioinformatic strategies that optimize specificity.
"We are thrilled to be able to offer this solution to the Indian market and ensure that hurdle of repeated tissue biopsies does not keep the physicians from having the most up-to-date information when making treatment decisions," Divya Mehta, Guardant's head of corporate development for Asia, the Middle East and Africa, said in a statement.
Financial terms of the deal were not disclosed.
Other tests that Core has arranged to market in India include Promega Biotech's MSI Analysis System, Precipio's ICE COLD-PCR liquid biopsy assays, and cancer risk and early detection tests from CellMax Life.